Israeli white blood cell biotech Macrocure sets terms for $75 million IPO

By
A A A

Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, announced terms for its IPO on Friday. The Petach Tikva, Israel-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $264 million.

Another Israeli biotech targeting severe burns and hard-to-heal wounds, MediWound ( MDWD ), went public in March.

Macrocure, which was founded in 2008, plans to list on the NASDAQ under the symbol MCUR. Credit Suisse and Jefferies are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: MDWD , MCUR

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Visualizing Healthcare MG
Visualizing Healthcare MG           
Power on/Power Off IPC
Power on/Power Off IPC              
Spot the Dropout RRC
Spot the Dropout RRC                
Power on/Power Off
Power on/Power Off                  

Stocks

Referenced

Most Active by Volume

105,858,039
  • $10.50 ▲ 3.04%
105,433,684
  • $29.22 ▲ 4.62%
72,716,790
  • $16.36 ▼ 0.49%
51,381,067
  • $113.29 ▲ 0.33%
47,443,661
  • $2.39 ▲ 4.82%
45,387,229
  • $5.78 ▲ 0.87%
45,001,566
  • $105.62 ▼ 0.02%
42,379,286
  • $28.42 ▲ 2.53%
As of 8/28/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com